Publications by authors named "Lavarnan Sivanathan"
Acute pain management of patients on buprenorphine for opioid use disorder remains a challenge. The buprenorphine extended-release depot injection which lasts for 1 month and has a higher plasma concentration of buprenorphine compared to the sublingual formulation is increasingly being used in patients. Acute pain management of patients on buprenorphine depot remains a challenge because waiting for the washout of the medication is not feasible and discontinuation is challenging because it requires surgical excision.
View Article and Find Full Text PDFBackground: Obstructive sleep apnea is underdiagnosed in surgical patients. The cost-effectiveness of obstructive sleep apnea screening is unknown. This study's objective was to evaluate the cost-effectiveness of preoperative obstructive sleep apnea screening (1) perioperatively and (2) including patients' remaining lifespans.
View Article and Find Full Text PDFPurpose: Survivors of critical illness may be at higher risk of developing subsequent mental illness. We sought to determine the risk of new mental illness diagnoses across a large population of intensive care unit (ICU) survivors compared with hospitalized patients.
Methods: Population-based study (2005-2015) conducted in adults hospitalized in Ontario, Canada.
Low-dose metronomic (LDM) chemotherapy is a beneficial and very well-tolerated form of chemotherapy utilization characterized by the frequent and uninterrupted administration of low doses of conventional chemotherapeutic agents over prolonged periods of time. While patients resistant to standard maximum tolerated dose (MTD) chemotherapy may still benefit from LDM chemotherapy, there is a lack of predictive markers of response to LDM chemotherapy. We searched the MEDLINE, EMBASE, CENTRAL and PubMed databases for correlative studies conducted as part of LDM chemotherapy trials in order to identify the most promising biomarker candidates.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the gene expression changes that occur when prostate cancer cells are passed through an in vivo model, which may impact the analysis of therapeutic resistance.
- The research compares the expression profiles of original PC-3 prostate cancer cells to those re-derived after in vivo passage in mice, identifying significant gene expression differences.
- Results show that notable transcripts associated with cancer progression are altered, suggesting that using in vivo passaged control cells is more appropriate for studying therapeutic resistance than comparing against parental cell lines.